Solutions
About Us
Insights
Careers

Split-Dose Cisplatin Use, Eligibility Criteria, and Drivers for Treatment Choice in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a Large International Physician Survey. O’Dwyer R, Junker S, Szulkin R, Kienzle S, Kearney M, Sridhar SS. Cancers (Basel). 2025

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma. Ramaswami R, Kask AS, D’Amico L, Menon MP, Lurain K, Yarchoan R, Ekwede I, Couey P, Burnham E, Angeldekao A, Ha Lee B, Kaiser JC, Cheever M, Uldrick TS, Kwok LL, Wright A, Fling SP, Wang CJ. J Immunother Cancer. 2025

Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma. Chng WJ, Wu DB, Wu CK, Springford A, Daly CH, Jung SH. Clin Lymphoma Myeloma

Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison. Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Cruz IP, Hlavacek P. J Comp Eff Res. 2025

Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis. Barthélémy P, Musat MG, Moradian H, Kearney M. Future Oncol. 2025

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Shah B, Sandin R, Liu Y, Bobolts LR, Hu Y, Mol I, Schepart A, Hughes DM, Hart J, Hlavacek P. Clinicoecon Outcomes Res. 2025

Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study. Bolleddula J, Scheible H, Huber F, Seithel-Keuth A, Schieferstein H, Vagge DS, Mammasse N, Jaks E, Ferrer J, Moulin C, Dong J, Venkatakrishnan K, Papai Z. Clin Pharmacol Drug Dev. 2025

A Cost-Effectiveness Analysis for Avelumab as a First-Line Maintenance Treatment of Advanced Urothelial Carcinoma in the Netherlands. Smalbrugge D, Walsteijn T, de Feijter J, Suelmann B, Kearney M, Benedict A, Kapetanakis V, van Beekhuizen S. Oncol Ther. 2025

The modified combo i3 + 3 design for novel-novel combination dose-finding trials in oncology. Liu J, Yuan S, Deng Q, Ji Y. Contemp Clin Trials. 2025

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study. Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C. Lung Cancer. 2025